Recovery · Compound
GLOW Blend is a research blend of BPC-157, TB-500 and GHK-Cu. The blend itself has not been studied; each component's evidence is set out below.
GLOW Blend is a single lyophilised vial holding three research peptides together: the copper tripeptide GHK-Cu, the synthetic peptide BPC-157, and TB-500, a fragment related to thymosin beta-4.
Our partner and supplier Primara Labs lists its composition as: Lyophilized powder, GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg / vial.
It is sold as research material. It is not a registered medicine in the Philippines or anywhere else, and no regulator has reviewed the combination.
There is no mechanism for the blend as a whole, because the blend has not been studied. What exists is laboratory work on each component alone.
GHK-Cu binds copper. In cell and animal work it drives both the building and the breakdown of collagen and adjusts the enzymes that remodel tissue.
BPC-157 has no identified receptor. Pathways proposed for it, such as growth-factor signalling, new blood vessel formation and lower inflammatory signalling, come from animal and cell studies, and none has been shown in people.
TB-500 is described in the analytical literature as the acetylated form of LKKTETQ, the actin-binding stretch of thymosin beta-4. A 2024 cell study found the wound-healing activity came from a breakdown product rather than TB-500 itself.
GLOW Blend itself has not been studied as a combination. No trial, human or animal, has tested these components together. What follows is what research found for each component on its own, strongest evidence first.
Strongest evidence found: small human studies.
A small uncontrolled pilot in 12 women with interstitial cystitis reported complete symptom resolution in 10, with no placebo or comparison group, so the result cannot separate the peptide from other causes. Source: PubMed 39325560
A retrospective phone survey of 16 clinic patients found 14 reporting knee pain relief; it had no control group and no validated outcome measure. Source: PubMed 34324435
In an animal study, rats with a cut Achilles tendon given BPC-157 showed better mechanical, functional and microscopic healing than rats given saline. No human trial has tested this. Source: J Orthop Res 2003
In an animal study, rats with a surgically cut knee ligament healed better on functional, mechanical and tissue measures over 90 days with BPC-157. This is animal evidence only. Source: J Orthop Res 2010
Strongest evidence found: animal and cell.
In an animal study, the seven-amino-acid thymosin beta-4 fragment LKKTETQ helped skin wounds repair in aged and diabetic mice about as well as the full-length protein. There is no human trial of the fragment. Source: Wound Repair Regen 2003
In a cell scratch-wound test, a TB-500 breakdown product (Ac-LKKTE) showed wound-healing activity while TB-500 itself did not. This is cell evidence only. Source: J Chromatogr B 2024
Strongest evidence found: small human studies.
A randomised, evaluator-blinded trial of a topical GHK-Cu gel on diabetic foot ulcers reported median closure of 98.5% against 60.8% with an inactive gel; the abstract gives neither the trial's size nor its phase. Source: Wound Repair Regen 1994
In 13 randomised patients recovering from laser skin resurfacing, GHK-Cu skin care made no measurable difference to redness, wrinkles or blinded ratings, although patients rated their own skin higher. Source: Arch Facial Plast Surg 2006
In an animal study of knee ligament reconstruction in rats, GHK-Cu reduced knee laxity at 6 weeks, but the difference was gone by 12 weeks. Source: J Orthop Res 2015
In cell culture, GHK-Cu shortened the doubling time of normal and irradiated human skin fibroblasts and raised their early growth-factor output. This is cell evidence only. Source: Arch Facial Plast Surg 2005
As with its benefits, nothing is known about the side effects of GLOW Blend as a combination. The record for each component is below.
No human trial in the datasets reports adverse-event rates for BPC-157, whose human evidence is limited to small human studies with no completed randomised trial identified. Without controlled data, its safety in people is unknown rather than established.
No human trial in the datasets reports adverse-event rates for TB-500, which has been studied in animals and cells only. Without controlled data, its safety in people is unknown rather than established.
No human trial in the datasets reports adverse-event rates for GHK-Cu, whose human evidence is limited to small human studies (2 completed randomised trials identified). Without controlled data, its safety in people is unknown rather than established.
Checked 23 September 2026. Primary source
Checked 23 September 2026. Primary source
Checked 23 September 2026. Primary source
How Philippine registration and prescription rules work, and what an unregistered product is under the law, is covered in the regulation hub, and every compound's status side by side is on the status page. This is general information, not legal advice.
Three peptides in one vial. As listed by our partner and supplier Primara Labs: Lyophilized powder, GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg / vial.
No. No trial of any kind has tested the three together. Of the components, GHK-Cu and BPC-157 have small human studies (GHK-Cu applied to the skin, BPC-157 in uncontrolled reports), and TB-500 has animal and cell data only.
No registration for the blend or its components was found in the regulatory records this site draws on. The status of each component is set out in the regulatory section above. This is general information, not legal advice.
The supply index covers what to ask a seller before paying, and why quoted prices vary so widely.
Risk · Disclosure · Editorial Status
This page is editorial information for adults researching peptide therapy. It is not medical advice, not a prescription, and not an endorsement of any specific product, supplier, or protocol. Side effects can be serious and individual response varies. Talk to a licensed physician (ideally one with peptide-specific clinical experience) before starting any compound, adjusting a dose, or discontinuing therapy.
In the Philippines, GLP-1 medications are prescription-only under FDA Philippines regulation. Research-grade peptides occupy a regulatory gray area: import for personal research use is generally tolerated, but the Bureau of Customs reserves the right to inspect and detain shipments. Do not import for resale.
